• Molecular NameValganciclovir
  • SynonymCymeval; L-valine, ester with ganciclovir; valganciclovir
  • Weight354.367
  • Drugbank_IDDB01610
  • ACS_NO175865-59-5
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-1.53
  • pkaN/A
  • LogD (pH=7, predicted)-2.22
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.43
  • LogSw (predicted, AB/LogsW2.0)7.04
  • Sw (mg/ml) (predicted, ACD/Labs)2.06
  • No.of HBond Donors6
  • No.of HBond Acceptors11
  • No.of Rotatable Bonds9
  • TPSA167.08
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antiviral medication used to treat cytomegalovirus infections.
  • Absorption_valueN/A
  • Absorption (description)Valganciclovir is well absorbed from the gastrointestinal tract and the absolute bioavailability from valganciclovir tablets (following administration with food) is approximately 60%.
  • Caco_2N/A
  • Bioavailability61.0
  • Protein binding1.5
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHydrolysed to ganciclovir
  • Half life4 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityIt is expected that an overdose of valganciclovir could also possibly result in increased renal toxicity.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A